Breakthrough Research Presented at International Radiology Meeting Finds CAD Highly Effective in Detecting Missed Cancers

The multicenter study evaluated the performance of computer-aided detection (CAD) with computed radiography (CR) for mammography in the detection of breast cancers that had previously been missed. Dr. Brem's findings showed that of the confirmed cancers, 55 percent were missed by at least one of the six readers. CAD correctly pinpointed 88 percent of all cancers, adding further evidence of the clinical need for CAD with CR.

"Even under ideal circumstances, it can be difficult for radiologists to determine what abnormalities in a mammogram could be cancerous and warrant closer evaluation," said Dr. Brem. "Our research confirmed that by adding computer-aided detection, readers are better equipped to detect breast cancers that otherwise would not be identified."

In addition, special sessions on breast CAD including real-time demonstrations, panel discussions and clinical evaluations of iCAD's technology were shared at CARS.

"iCAD is dedicated to providing radiologists with the tools they need to help them find more cancers at an earlier stage," said Ken Ferry, President and CEO of iCAD. "Dr. Brem's study utilizing SecondLook CAD further supports the comprehensive body of evidence that has helped iCAD become a global market leader in CAD solutions for breast, prostate and colon cancers."

Dr. Brem is a member of iCAD's Board of Directors.

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR)), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Since receiving FDA approval for the Company's first breast cancer detection product in 2002, over 3,100 iCAD systems have been placed in healthcare practices worldwide. iCAD's solutions aid in the early detection of the most prevalent cancers including breast, prostate and in the future, colon and lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe" , "demonstrate" , "intend" , "expect" , "estimate" , "anticipate" , "likely" , and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.

For iCAD:
Darlene Deptula-Hicks, 603-882-5200 x7944
ddeptula@icadmed.com
or
For Investor Relations:
Lippert/Heilshorn & Associates
Anne Marie Fields, 212-838-3777 x6604
afields@lhai.com
or
For media inquiries:
MS&L PR
Liza Heapes, 617-369-8787
liza.heapes@mslworldwide.com